Report
Debbie Wang
EUR 100.00 For Business Accounts Only

Edwards Lifesciences Posts Strong 2Q With Solid TAVR Demand; Raising Our FVE

Edwards Lifesciences delivered impressive second-quarter performance and is tracking along with our full-year projections. While we haven’t made any changes to our estimates through 2023, we have boosted our fair value estimate to $170 after baking in more optimistic estimates of longer-term growth and cash flow realized since our last update. We see little to change our view of Edwards’ narrow economic moat. However, we think it is worth monitoring the firm’s stable moat trend over the next 12 ...
Underlying
EDWARDS LIFESCIENCES CORP

Edwards Lifesciences is engaged in patient-focused medical for structural heart disease, as well as critical care and surgical monitoring. The company is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company is also engaged in hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Debbie Wang

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch